Friday a Long White Candlestick was formed. This shows that the prices advanced significantly from open to close during the day under strong buying pressure.
Monday CLSN will climb towards a blue sky run continuation. $8.35 marking the spot where blue sky begins.
2013 will be an exciting year for Celsion shareholders with Phase III topline results release for ThermoDox schedule for January. Very little downside risk as shareholders place bets on the nano encapsulation delivery system that's proven itself to work in previous trials. This encapsulation delivers an already proven drug to the specific tumor site and allows less systemic toxicity.
The Phase III trial has Fast Track Designation from the FDA and has received Orphan Drug Designation in both the U.S. and Europe, protecting the company's platform for primary liver disease from competition and increasing its profitability for up to 7 years after the approval date. Additionally, positive data would also serve to validate the company's platform and give evidence of use for other indications.
$12 by January prior to data release likely.
This review establishes an opinion of: MARKET OUTPERFORM price target $24 after data release.
Investors will probably agree with this review using their due diligence/fact checking.